{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:02:17Z","timestamp":1790186537785,"version":"4.1.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40123-024-01001-1","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T16:02:14Z","timestamp":1722528134000},"page":"2303-2329","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Systematic Literature Reviews Comparing the Long-Term Safety Outcomes for the Port Delivery System with Ranibizumab (PDS) Versus Other Ocular Implants"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7850-8515","authenticated-orcid":false,"given":"Nancy M.","family":"Holekamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1088-8863","authenticated-orcid":false,"given":"Manejeh","family":"Yaqub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9457-2477","authenticated-orcid":false,"given":"Shrirang V.","family":"Ranade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6806-6071","authenticated-orcid":false,"given":"Ronald A.","family":"Cantrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-7599","authenticated-orcid":false,"given":"Sheena","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1982-5005","authenticated-orcid":false,"given":"Gus","family":"Gazzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"issue":"2","key":"1001_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u201316.","journal-title":"Lancet Glob Health"},{"issue":"12","key":"1001_CR2","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","volume":"5","author":"SR Flaxman","year":"2017","unstructured":"Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(12):e1221\u201334.","journal-title":"Lancet Glob Health"},{"issue":"11","key":"1001_CR3","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580\u201391.","journal-title":"Ophthalmology"},{"issue":"1","key":"1001_CR4","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1016\/j.ophtha.2019.09.024","volume":"127","author":"CJ Flaxel","year":"2020","unstructured":"Flaxel CJ, Adelman RA, Bailey ST, et al. Age-related macular degeneration preferred practice pattern\u00ae. Ophthalmology. 2020;127(1):P1\u201365.","journal-title":"Ophthalmology"},{"key":"1001_CR5","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.2147\/OPTH.S185052","volume":"12","author":"KL Spooner","year":"2018","unstructured":"Spooner KL, Mhlanga CT, Hong TH, Broadhead GK, Chang AA. The burden of neovascular age-related macular degeneration: a patient\u2019s perspective. Clin Ophthalmol. 2018;12:2483\u201391.","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"1001_CR6","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.oret.2018.01.006","volume":"2","author":"TA Ciulla","year":"2018","unstructured":"Ciulla TA, Huang F, Westby K, Williams DF, Zaveri S, Patel SC. Real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States. Ophthalmol Retina. 2018;2(7):645\u201353.","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"1001_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.oret.2019.09.009","volume":"4","author":"AM Khanani","year":"2020","unstructured":"Khanani AM, Skelly A, Bezlyak V, Griner R, Torres LR, Sagkriotis A. SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the United States. Ophthalmol Retina. 2020;4(2):122\u201333.","journal-title":"Ophthalmol Retina"},{"issue":"8","key":"1001_CR8","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","volume":"126","author":"PA Campochiaro","year":"2019","unstructured":"Campochiaro PA, Marcus DM, Awh CC, et al. The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial. Ophthalmology. 2019;126(8):1141\u201354.","journal-title":"Ophthalmology"},{"issue":"8","key":"1001_CR9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.oret.2020.11.004","volume":"5","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Callanan D, Dreyer R, et al. End-of-study results for the Ladder phase 2 trial of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration. Ophthalmol Retina. 2021;5(8):775\u201387.","journal-title":"Ophthalmol Retina"},{"key":"1001_CR10","unstructured":"Susvimo [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2021."},{"issue":"3","key":"1001_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","volume":"129","author":"NM Holekamp","year":"2022","unstructured":"Holekamp NM, Campochiaro PA, Chang MA, et al. Archway randomized phase 3 trial of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022;129(3):295\u2013307.","journal-title":"Ophthalmology"},{"issue":"7","key":"1001_CR12","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ophtha.2023.02.024","volume":"130","author":"C Regillo","year":"2023","unstructured":"Regillo C, Berger B, Brooks L, et al. Archway phase 3 trial of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration 2-year results. Ophthalmology. 2023;130(7):735\u201347.","journal-title":"Ophthalmology"},{"key":"1001_CR13","unstructured":"Khanani AM. Port Delivery System with ranibizumab in patients with diabetic macular edema: primary analysis results of the phase 3 Pagoda trial. Presented at: Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration; February 10\u201311, 2023; Virtual."},{"key":"1001_CR14","unstructured":"Pieramici D. Port Delivery System with ranibizumab in patients with diabetic retinopathy: primary analysis results of the phase 3 Pavilion trial. Presented at: Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration; February 10\u201311, 2023; Virtual."},{"key":"1001_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","volume":"349","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.","journal-title":"BMJ"},{"key":"1001_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"1001_CR17","unstructured":"Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2011. Available from: www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 25 May 2023."},{"issue":"6","key":"1001_CR18","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ophtha.2022.01.015","volume":"129","author":"MA Singer","year":"2022","unstructured":"Singer MA, Sheth V, Mansour SE, Coughlin B, Gonzalez VH. Three-year safety and efficacy of the 0.19-mg fluocinolone acetonide intravitreal implant for diabetic macular edema: the PALADIN study. Ophthalmology. 2022;129(6):605\u201313.","journal-title":"Ophthalmology"},{"issue":"3","key":"1001_CR19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1080\/02713683.2016.1185130","volume":"42","author":"JK Parihar","year":"2017","unstructured":"Parihar JK, Jain VK, Kaushik J, Mishra A. Pars plana-modified versus conventional Ahmed glaucoma valve in patients undergoing penetrating keratoplasty: a prospective comparative randomized study. Curr Eye Res. 2017;42(3):436\u201342.","journal-title":"Curr Eye Res"},{"issue":"10","key":"1001_CR20","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","volume":"121","author":"DS Boyer","year":"2014","unstructured":"Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904\u201314.","journal-title":"Ophthalmology"},{"issue":"6","key":"1001_CR21","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ajo.2010.01.025","volume":"149","author":"N Nassiri","year":"2010","unstructured":"Nassiri N, Kamali G, Rahnavardi M, et al. Ahmed glaucoma valve and single-plate Molteno implants in treatment of refractory glaucoma: a comparative study. Am J Ophthalmol. 2010;149(6):893\u2013902.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"1001_CR22","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1097\/IJG.0000000000001295","volume":"28","author":"K Gillmann","year":"2019","unstructured":"Gillmann K, Bravetti GE, Mermoud A, Rao HL, Mansouri K. XEN gel stent in pseudoexfoliative glaucoma: 2-year results of a prospective evaluation. J Glaucoma. 2019;28(8):676\u201384.","journal-title":"J Glaucoma"},{"issue":"7","key":"1001_CR23","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/IJG.0000000000001520","volume":"29","author":"K Gillmann","year":"2020","unstructured":"Gillmann K, Bravetti GE, Rao HL, Mermoud A, Mansouri K. Bilateral XEN stent implantation: a long-term prospective study of the difference in outcomes between first-operated and fellow eyes. J Glaucoma. 2020;29(7):536\u201341.","journal-title":"J Glaucoma"},{"key":"1001_CR24","doi-asserted-by":"publisher","first-page":"7424376","DOI":"10.1155\/2019\/7424376","volume":"2019","author":"M Fraczkiewicz-Skok","year":"2019","unstructured":"Fraczkiewicz-Skok M, Konopinska J, Mariak Z, Rekas M. Comparison of ExPress implantation and partial deep sclerectomy combined with ExPress implantation and simultaneous phacoemulsification. J Ophthalmol. 2019;2019:7424376.","journal-title":"J Ophthalmol"},{"issue":"2","key":"1001_CR25","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ajo.2013.09.014","volume":"157","author":"PA Netland","year":"2014","unstructured":"Netland PA, Sarkisian SR Jr, Moster MR, et al. Randomized, prospective, comparative trial of EX-PRESS glaucoma filtration device versus trabeculectomy (XVT Study). Am J Ophthalmol. 2014;157(2):433\u201340.e3.","journal-title":"Am J Ophthalmol"},{"key":"1001_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ajo.2015.11.023","volume":"163","author":"DL Budenz","year":"2016","unstructured":"Budenz DL, Feuer WJ, Barton K, et al. Postoperative complications in the Ahmed Baerveldt comparison study during five years of follow-up. Am J Ophthalmol. 2016;163:75\u201382.e3.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"1001_CR27","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.ophtha.2014.01.036","volume":"121","author":"K Barton","year":"2014","unstructured":"Barton K, Feuer WJ, Budenz DL, et al. Three-year treatment outcomes in the Ahmed Baerveldt comparison study. Ophthalmology. 2014;121(8):1547\u201357.e1.","journal-title":"Ophthalmology"},{"issue":"11","key":"1001_CR28","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.ophtha.2011.05.003","volume":"118","author":"PG Christakis","year":"2011","unstructured":"Christakis PG, Tsai JC, Zurakowski D, Kalenak JW, Cantor LB, Ahmed IIK. The Ahmed versus Baerveldt study: design, baseline patient characteristics, and intraoperative complications. Ophthalmology. 2011;118(11):2172\u20139.","journal-title":"Ophthalmology"},{"issue":"11","key":"1001_CR29","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/j.ophtha.2013.04.018","volume":"120","author":"PG Christakis","year":"2013","unstructured":"Christakis PG, Tsai JC, Kalenak JW, et al. The Ahmed versus Baerveldt study: three-year treatment outcomes. Ophthalmology. 2013;120(11):2232\u201340.","journal-title":"Ophthalmology"},{"issue":"10","key":"1001_CR30","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/j.ophtha.2016.06.035","volume":"123","author":"PG Christakis","year":"2016","unstructured":"Christakis PG, Kalenak JW, Tsai JC, et al. The Ahmed versus Baerveldt study: five-year treatment outcomes. Ophthalmology. 2016;123(10):2093\u2013102.","journal-title":"Ophthalmology"},{"issue":"5","key":"1001_CR31","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.ajo.2009.06.018","volume":"148","author":"SJ Gedde","year":"2009","unstructured":"Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL. Three-year follow-up of the Tube Versus Trabeculectomy study. Am J Ophthalmol. 2009;148(5):670\u201384.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1001_CR32","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ajo.2011.10.026","volume":"153","author":"SJ Gedde","year":"2012","unstructured":"Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012;153(5):789\u2013803.e2.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1001_CR33","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ajo.2011.10.024","volume":"153","author":"SJ Gedde","year":"2012","unstructured":"Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC. Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol. 2012;153(5):804\u201314.e1.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"1001_CR34","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/aos.14265","volume":"98","author":"E Islamaj","year":"2020","unstructured":"Islamaj E, Wubbels RJ, de Waard PWT. Primary Baerveldt versus trabeculectomy study after 5 years of follow-up. Acta Ophthalmol. 2020;98(4):400\u20137.","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"1001_CR35","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1097\/IJG.0b013e318182ed9e","volume":"17","author":"A Bissig","year":"2008","unstructured":"Bissig A, Rivier D, Zaninetti M, Shaarawy T, Mermoud A, Roy S. Ten years follow-up after deep sclerectomy with collagen implant. J Glaucoma. 2008;17(8):680\u20136.","journal-title":"J Glaucoma"},{"issue":"3","key":"1001_CR36","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/IJG.0000000000000131","volume":"25","author":"SK Law","year":"2016","unstructured":"Law SK, Kornmann HL, Giaconi JA, Kwong A, Tran E, Caprioli J. Early aqueous suppressant therapy on hypertensive phase following glaucoma drainage device procedure: a randomized prospective trial. J Glaucoma. 2016;25(3):248\u201357.","journal-title":"J Glaucoma"},{"issue":"3","key":"1001_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ophtha.2019.10.002","volume":"127","author":"SJ Gedde","year":"2020","unstructured":"Gedde SJ, Feuer WJ, Lim KS, et al. Treatment outcomes in the primary tube versus trabeculectomy study after 3 years of follow-up. Ophthalmology. 2020;127(3):333\u201345.","journal-title":"Ophthalmology"},{"issue":"9","key":"1001_CR38","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1136\/bjophthalmol-2015-307161","volume":"100","author":"JM Gonzalez-Rodriguez","year":"2016","unstructured":"Gonzalez-Rodriguez JM, Trope GE, Drori-Wagschal L, Jinapriya D, Buys YM. Comparison of trabeculectomy versus Ex-PRESS: 3-year follow-up. Br J Ophthalmol. 2016;100(9):1269\u201373.","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"1001_CR39","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ogla.2019.03.011","volume":"2","author":"K Mansouri","year":"2019","unstructured":"Mansouri K, Bravetti GE, Gillmann K, Rao HL, Ch\u2019ng TW, Mermoud A. Two-year outcomes of XEN gel stent surgery in patients with open-angle glaucoma. Ophthalmol Glaucoma. 2019;2(5):309\u201318.","journal-title":"Ophthalmol Glaucoma"},{"issue":"6","key":"1001_CR40","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jcrs.2003.10.035","volume":"30","author":"T Shaarawy","year":"2004","unstructured":"Shaarawy T, Mansouri K, Schnyder C, Ravinet E, Achache F, Mermoud A. Long-term results of deep sclerectomy with collagen implant. J Cataract Refract Surg. 2004;30(6):1225\u201331.","journal-title":"J Cataract Refract Surg"},{"issue":"4","key":"1001_CR41","first-page":"629","volume":"11","author":"N Bao","year":"2018","unstructured":"Bao N, Jiang ZX, Coh P, Tao LM. Long-term outcomes of uveitic glaucoma treated with Ahmed valve implant in a series of Chinese patients. Int J Ophthalmol. 2018;11(4):629\u201334.","journal-title":"Int J Ophthalmol"},{"issue":"7","key":"1001_CR42","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/ceo.13965","volume":"49","author":"HG Kang","year":"2021","unstructured":"Kang HG, Jun JW, Choi EY, et al. Comparison of long-term surgical outcomes for scleral-fixated versus retropupillary iris-claw intraocular lens. Clin Exp Ophthalmol. 2021;49(7):686\u201395.","journal-title":"Clin Exp Ophthalmol"},{"key":"1001_CR43","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12886-022-02493-w","volume":"22","author":"YK Kang","year":"2022","unstructured":"Kang YK, Shin JP, Kim DW. Long-term surgical outcomes of Ahmed valve implantation in refractory glaucoma according to the type of glaucoma. BMC Ophthalmol. 2022;22:270.","journal-title":"BMC Ophthalmol"},{"issue":"11","key":"1001_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187533","volume":"12","author":"CK Lee","year":"2017","unstructured":"Lee CK, Ma KT, Hong YJ, Kim CY. Long-term clinical outcomes of Ahmed valve implantation in patients with refractory glaucoma. PLoS ONE. 2017;12(11): e0187533.","journal-title":"PLoS ONE"},{"issue":"2","key":"1001_CR45","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/jcm9020416","volume":"9","author":"J Lee","year":"2020","unstructured":"Lee J, Park CK, Jung KI. Initial glaucoma medication in the hypertensive phase following Ahmed valve implantation: a comparison of results achieved using aqueous suppressants and prostaglandin analogs. J Clin Med. 2020;9(2):416.","journal-title":"J Clin Med"},{"key":"1001_CR46","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12886-022-02297-y","volume":"22","author":"Y Park","year":"2022","unstructured":"Park Y, Cho KJ. Posterior segment complications of Ahmed valve implantation. BMC Ophthalmol. 2022;22:78.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"1001_CR47","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/bjophthalmol-2021-319999","volume":"29","author":"S Gnanavelu","year":"2021","unstructured":"Gnanavelu S, Puthuran GV, Chiranjeevi KP, et al. Intermediate-term outcomes of the Aurolab aqueous drainage implant in neovascular glaucoma. Br J Ophthalmol. 2021;29(3):355\u201360.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1001_CR48","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s10792-021-02047-x","volume":"42","author":"J Kaushik","year":"2022","unstructured":"Kaushik J, Parihar JKS, Singh A, et al. Evaluation of primary Ahmed glaucoma valve implantation in post-traumatic angle recession glaucoma in Indian eyes. Int Ophthalmol. 2022;42(3):817\u201327.","journal-title":"Int Ophthalmol"},{"issue":"4","key":"1001_CR49","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bjophthalmol-2019-313942","volume":"104","author":"SS Pandav","year":"2020","unstructured":"Pandav SS, Seth NG, Thattaruthody F, et al. Long-term outcome of low-cost glaucoma drainage device (Aurolab aqueous drainage implant) compared with Ahmed glaucoma valve. Br J Ophthalmol. 2020;104(4):557\u201362.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1001_CR50","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/IJG.0000000000001749","volume":"30","author":"SS Pandav","year":"2021","unstructured":"Pandav SS, Thattaruthody F, Singh SR, et al. Long-term outcome of Ahmed glaucoma valve implantation in eyes with intractably raised intraocular pressure following pars plana vitrectomy. J Glaucoma. 2021;30(4):362\u20137.","journal-title":"J Glaucoma"},{"issue":"4","key":"1001_CR51","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1177\/1120672120946279","volume":"31","author":"N Tojo","year":"2021","unstructured":"Tojo N, Hayashi A. The results of Baerveldt glaucoma implant surgery performed with the scleral flap and patch technique. Eur J Ophthalmol. 2021;31(4):1844\u20139.","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"1001_CR52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5005\/jp-journals-10078-1252","volume":"13","author":"N Tojo","year":"2019","unstructured":"Tojo N, Hayashi A, Otsuka M. Evaluation of early postoperative intraocular pressure for success after Ex-Press surgery. J Curr Glaucoma Pract. 2019;13(2):55\u201361.","journal-title":"J Curr Glaucoma Pract"},{"issue":"5","key":"1001_CR53","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10792-020-01286-8","volume":"40","author":"N Tojo","year":"2020","unstructured":"Tojo N, Numata A, Hayashi A. Factors influencing the reduction in corneal endothelial cells after Ex-Press surgery. Int Ophthalmol. 2020;40(5):1201\u20138.","journal-title":"Int Ophthalmol"},{"issue":"8","key":"1001_CR54","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1097\/IJG.0000000000001004","volume":"27","author":"JQH Choo","year":"2018","unstructured":"Choo JQH, Chen ZD, Koh V, et al. Outcomes and complications of Ahmed tube implantation in Asian eyes. J Glaucoma. 2018;27(8):733\u20138.","journal-title":"J Glaucoma"},{"issue":"11","key":"1001_CR55","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/IJG.0000000000001610","volume":"29","author":"N Kitnarong","year":"2020","unstructured":"Kitnarong N, Srikulsasitorn B, Aurboonsong T. Glycerin-preserved human-donor corneoscleral patch grafts for glaucoma drainage devices. J Glaucoma. 2020;29(11):1065\u20139.","journal-title":"J Glaucoma"},{"issue":"2","key":"1001_CR56","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1080\/09273948.2019.1578380","volume":"28","author":"C Alba-Linero","year":"2020","unstructured":"Alba-Linero C, Sala-Puigdollers A, Romero B, Llorenc V, Adan A, Zarranz-Ventura J. Long-term intravitreal dexamethasone implant outcomes in uveitis. Ocul Immunol Inflamm. 2020;28(2):228\u201337.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"1001_CR57","doi-asserted-by":"publisher","first-page":"220","DOI":"10.5301\/ejo.5000914","volume":"27","author":"C Quijano","year":"2017","unstructured":"Quijano C, Alkabes M, Gomez-Resa M, Olenik A, Villani E, Corcostegui B. Scleral buckling in phakic uncomplicated primary rhegmatogenous retinal detachment: long-term outcomes. Eur J Ophthalmol. 2017;27(2):220\u20135.","journal-title":"Eur J Ophthalmol"},{"issue":"8","key":"1001_CR58","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1136\/bjophthalmol-2019-313870","volume":"104","author":"IE Gabbay","year":"2020","unstructured":"Gabbay IE, Allen F, Morley C, Pearsall T, Bowes OM, Ruben S. Efficacy and safety data for the XEN45 implant at 2 years: a retrospective analysis. Br J Ophthalmol. 2020;104(8):1125\u201330.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"1001_CR59","doi-asserted-by":"publisher","first-page":"e753","DOI":"10.1111\/aos.14989","volume":"100","author":"M Figus","year":"2022","unstructured":"Figus M, Loiudice P, Passani A, et al. Long-term outcome of supraciliary gold micro shunt in refractory glaucoma. Acta Opthalmol. 2022;100(3):e753\u20139.","journal-title":"Acta Opthalmol"},{"key":"1001_CR60","doi-asserted-by":"publisher","first-page":"2321922","DOI":"10.1155\/2021\/2321922","volume":"2021","author":"K Lewczuk","year":"2021","unstructured":"Lewczuk K, Konopinska J, Jablonska J, et al. XEN glaucoma implant for the management of operated uncontrolled glaucoma: results and complications during a long-term follow-up. J Ophthalmol. 2021;2021:2321922.","journal-title":"J Ophthalmol"},{"issue":"1","key":"1001_CR61","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41433-021-01443-y","volume":"36","author":"A Marta","year":"2022","unstructured":"Marta A, Vieira R, Figueiredo A, et al. Ahmed valve for secondary glaucoma in patients with hereditary transthyretin amyloidosis. Eye. 2022;36(1):111\u20138.","journal-title":"Eye"},{"issue":"4","key":"1001_CR62","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000452896","volume":"236","author":"S Pommier","year":"2016","unstructured":"Pommier S, Meyer F, Guigou S, et al. Long-term real-life efficacy and safety of repeated Ozurdex R injections and factors associated with macular edema resolution after retinal vein occlusion: the REMIDO 2 study. Ophthalmologica. 2016;236(4):186\u201392.","journal-title":"Ophthalmologica"},{"issue":"7","key":"1001_CR63","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/aos.13721","volume":"96","author":"WM van Hoefen","year":"2018","unstructured":"van Hoefen WM, Haan M, Rietveld E, van Rijn LJ. Donor sclera versus bovine pericardium as patch graft material in glaucoma implant surgery and the impact of a drainage suture. Acta Opthalmol. 2018;96(7):692\u20138.","journal-title":"Acta Opthalmol"},{"issue":"3","key":"1001_CR64","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ophtha.2014.09.002","volume":"122","author":"EJ Allan","year":"2015","unstructured":"Allan EJ, Khaimi MA, Jones JM, Ding K, Skuta GL. Long-term efficacy of the Baerveldt 250 mm2 compared with the Baerveldt 350 mm2 implant. Ophthalmology. 2015;122(3):486\u201393.","journal-title":"Ophthalmology"},{"issue":"4","key":"1001_CR65","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3928\/23258160-20150422-10","volume":"46","author":"MR Banitt","year":"2015","unstructured":"Banitt MR, Feuer WJ, Schiffman JC, Parrish RK 2nd. Adverse vitreoretinal outcomes of glaucoma drainage devices based on verified and unverified financial claims data. Ophthalmic Surg Lasers Imaging Retina. 2015;46(4):463\u201370.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"3","key":"1001_CR66","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ogla.2021.10.011","volume":"5","author":"ER Craven","year":"2022","unstructured":"Craven ER, Singh IP, Yu TM, Rhoten S, Sadruddin OR, Sheybani A. Reoperation rates and disease costs for primary open-angle glaucoma patients in the United States treated with incisional glaucoma surgery. Ophthalmol Glaucoma. 2022;5(3):297\u2013305.","journal-title":"Ophthalmol Glaucoma"},{"issue":"9","key":"1001_CR67","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1097\/IJG.0000000000000515","volume":"25","author":"AF Resende","year":"2016","unstructured":"Resende AF, Moster MR, Patel NS, et al. Ahmed versus Baerveldt glaucoma drainage implantation in patients with markedly elevated intraocular pressure (\u226530 mm Hg). J Glaucoma. 2016;25(9):738\u201343.","journal-title":"J Glaucoma"},{"issue":"6","key":"1001_CR68","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s00417-021-05095-2","volume":"259","author":"S Sinha","year":"2021","unstructured":"Sinha S, Ganjei AY, Ustaoglu M, et al. Effect of shunt type on rates of tube-cornea touch and corneal decompensation after tube shunt surgery in uveitic glaucoma. Graefes Arch Clin Exp Ophthalmol. 2021;259(6):1587\u201395.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"1001_CR69","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.oret.2020.11.002","volume":"5","author":"D Xu","year":"2021","unstructured":"Xu D, Belin PJ, Staropoli PC, et al. Clinical outcomes in sequential, bilateral rhegmatogenous retinal detachment: a multicenter, paired-eye analysis. Ophthalmol Retina. 2021;5(8):797\u2013804.","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"1001_CR70","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s00417-022-05562-4","volume":"260","author":"MN Bulut","year":"2022","unstructured":"Bulut MN, Goktas E, Bulut K, Simsek S. Two-year results of a novel sutureless scleral fixation surgery with the haptic hook technique. Graefes Arch Clini Exp Ophthalmol. 2022;260(6):1947\u201353.","journal-title":"Graefes Arch Clini Exp Ophthalmol"},{"issue":"6","key":"1001_CR71","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s10792-020-01311-w","volume":"40","author":"N Kandemir Besek","year":"2020","unstructured":"Kandemir Besek N, Alagoz N, Gumus G, et al. Long-term results of aphakia management by scleral fixation intraocular lens placement with knotless transscleral Z-suture method. Int Ophthalmol. 2020;40(6):1449\u201354.","journal-title":"Int Ophthalmol"},{"issue":"6","key":"1001_CR72","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/IJG.0000000000001813","volume":"30","author":"N Kapelushnik","year":"2021","unstructured":"Kapelushnik N, Singer R, Barkana Y, et al. Surgical outcomes of Ahmed glaucoma valve implantation without plate sutures: a 10-year retrospective study. J Glaucoma. 2021;30(6):502\u20137.","journal-title":"J Glaucoma"},{"issue":"10","key":"1001_CR73","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/IJG.0000000000001050","volume":"27","author":"Z Rabkin-Mainer","year":"2018","unstructured":"Rabkin-Mainer Z, Wolf A, Mathalone N, et al. Ex-PRESS miniature glaucoma shunt versus Ahmed glaucoma valve in the surgical treatment of glaucoma in pseudophakic patients. J Glaucoma. 2018;27(10):887\u201392.","journal-title":"J Glaucoma"},{"issue":"1","key":"1001_CR74","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jcjo.2016.06.007","volume":"52","author":"G Gdih","year":"2017","unstructured":"Gdih G, Jiang K. Graft-free Ahmed valve implantation through a 6 mm scleral tunnel. Can J Ophthalmol. 2017;52(1):85\u201391.","journal-title":"Can J Ophthalmol"},{"issue":"4","key":"1001_CR75","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jcjo.2022.02.012","volume":"58","author":"AA Szigiato","year":"2022","unstructured":"Szigiato AA, Touma S, Jabbour S, Lord F, Agoumi Y, Singh H. Efficacy of ab-interno gelatin microstent implantation in primary and refractory glaucoma. Can J Ophthalmol. 2022;58(4):328\u201337.","journal-title":"Can J Ophthalmol"},{"issue":"4","key":"1001_CR76","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/aos.14627","volume":"99","author":"T Rauchegger","year":"2021","unstructured":"Rauchegger T, Angermann R, Willeit P, Schmid E, Teuchner B. Two-year outcomes of minimally invasive XEN gel stent implantation in primary open-angle and pseudoexfoliation glaucoma. Acta Ophthalmol. 2021;99(4):369\u201375.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"1001_CR77","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1111\/aos.14886","volume":"100","author":"H Reitsamer","year":"2022","unstructured":"Reitsamer H, Vera V, Ruben S, et al. Three-year effectiveness and safety of the XEN gel stent as a solo procedure or in combination with phacoemulsification in open-angle glaucoma: a multicentre study. Acta Opthalmol. 2022;100(1):e233\u201345.","journal-title":"Acta Opthalmol"},{"issue":"3","key":"1001_CR78","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5005\/jp-journals-10008-1209","volume":"10","author":"RB Schimiti","year":"2016","unstructured":"Schimiti RB, Abe RY, Tavares CM, Vasconcellos JP, Costa VP. Intraocular pressure control after implantation of an Ahmed glaucoma valve in eyes with a failed trabeculectomy. J Curr Glaucoma Pract. 2016;10(3):97\u2013103.","journal-title":"J Curr Glaucoma Pract"},{"issue":"2","key":"1001_CR79","first-page":"240","volume":"11","author":"T Rotsos","year":"2018","unstructured":"Rotsos T, Tsioga A, Andreanos K, et al. Managing high risk glaucoma with the Ahmed valve implant: 20 years of experience. Int J Ophthalmol. 2018;11(2):240\u20134.","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"1001_CR80","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ogla.2020.06.012","volume":"4","author":"S Hau","year":"2021","unstructured":"Hau S, Bunce C, Barton K. Corneal endothelial cell loss after Baerveldt glaucoma implant surgery. Ophthalmol Glaucoma. 2021;4(1):20\u201331.","journal-title":"Ophthalmol Glaucoma"},{"key":"1001_CR81","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.2147\/OPTH.S181256","volume":"12","author":"A Tufail","year":"2018","unstructured":"Tufail A, Lightman S, Kamal A, et al. Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment uveitis. Clin Ophthalmol. 2018;12:2519\u201334.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"1001_CR82","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3341\/kjo.2017.0127","volume":"32","author":"J Jo","year":"2018","unstructured":"Jo J, Sung KR, Kim YJ. Influence of vitrectomy-related factors on the outcome of Ahmed glaucoma valve implantation. Korean J Ophthalmol. 2018;32(5):400\u20138.","journal-title":"Korean J Ophthalmol"},{"issue":"4","key":"1001_CR83","doi-asserted-by":"publisher","first-page":"e531","DOI":"10.1111\/aos.14605","volume":"99","author":"K Gillmann","year":"2021","unstructured":"Gillmann K, Bravetti GE, Rao HL, Mermoud A, Mansouri K. Combined and stand-alone XEN 45 gel stent implantation: 3-year outcomes and success predictors. Acta Ophthalmol. 2021;99(4):e531\u20139.","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"1001_CR84","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.oret.2022.05.011","volume":"6","author":"CC Awh","year":"2022","unstructured":"Awh CC, Barteselli G, Makadia S, et al. Management of key ocular adverse events in patients implanted with the Port Delivery System with ranibizumab. Ophthalmol Retina. 2022;6(11):1028\u201343.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"1001_CR85","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1177\/112067211002000117","volume":"20","author":"WC Stewart","year":"2010","unstructured":"Stewart WC, Kristoffersen CJ, Demos CM, Fsadni MG, Stewart JA. Incidence of conjunctival exposure following drainage device implantation in patients with glaucoma. Eur J Ophthalmol. 2010;20(1):124\u201330.","journal-title":"Eur J Ophthalmol"},{"key":"1001_CR86","unstructured":"Hwang DK, Blotner S, Cavichini Cordeiro M, Gune S, Jaycock P, Regillo C. Portal extension trial: three-year follow-up from phase 3 Archway trial of Port Delivery System with ranibizumab. Presented at: Asia-Pacific Academy of Ophthalmology Congress (APAO); February 23, 2023; Kuala Lumpur, Malaysia."},{"key":"1001_CR87","first-page":"2188","volume":"64","author":"J Howard","year":"2023","unstructured":"Howard J, Cavichini Cordeiro M, Singh N, Gune S. Long-term efficacy and safety of the Port Delivery System with ranibizumab in patients with nAMD: results from the Portal 5-year subgroup analysis. Invest Ophthalmol Vis Sci. 2023;64:2188.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-01001-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-024-01001-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-024-01001-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T14:41:17Z","timestamp":1724424077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-024-01001-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":87,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1007\/s40123-024-01001-1","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nancy M Holekamp reports employment by F. Hoffmann-La Roche Ltd. (visiting professor); consulting fees from Apellis, Bayer, Biogen, Boehringer Ingelheim, Cardinal, Clearside, EyePoint, Genentech, Inc., Gyroscope, Medpace, Medscape, Notal Vision, Novartis, Regeneron, Roche, Stealth, and Vial; speaker\u2019s bureaus for Apellis, Bausch\u2009+\u2009Lomb, Genentech, Inc., and Regeneron; contracted research for Gemini, Genentech, Inc., Gyroscope, and Notal Vision; data monitoring and safety committees for Editas, Ocuphire, and Roche; and stock or stock options in Apellis, Nacuity, and Notal Vision. Manejeh Yaqub reports employment by Genentech, Inc.; stock\/stock options in F. Hoffmann-La Roche Ltd.; and non-financial involvement with the Kashmiri Group of North America. Shrirang V Ranade and Ronald A Cantrell report employment by Genentech, Inc.; and stock\/stock options in F. Hoffmann-La Roche Ltd. Sheena Singh reports employment by Envision Pharma Group, which was contracted by Genentech, Inc.\/Roche (sponsor) for conducting and managing the systematic literature reviews on behalf of the sponsor. Gus Gazzard reports personal fees from Alcon, Allergan, Belkin, Equinox, Genentech, Inc.\/Roche, Glaukos, iStar, Ivantis, Lumibird, Reichert, Sight Sciences, Thea, Vialase, Visufarma, and Zeiss; grants from Belkin and Santen, Thea; and non-financial involvement with the patient advocacy group, GlaucomaUK, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}